About precipio - PRPO
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.
PRPO At a Glance
Precipio, Inc.
4 Science Park
New Haven, Connecticut 06511
| Phone | 1-203-787-7888 | Revenue | 18.53M | |
| Industry | Medical/Nursing Services | Net Income | -4,290,000.00 | |
| Sector | Health Services | 2024 Sales Growth | 21.945% | |
| Fiscal Year-end | 12 / 2025 | Employees | 60 | |
| View SEC Filings |
PRPO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.438 |
| Price to Book Ratio | 0.684 |
| Price to Cash Flow Ratio | 18.49 |
| Enterprise Value to EBITDA | -2.953 |
| Enterprise Value to Sales | 0.431 |
| Total Debt to Enterprise Value | 0.157 |
PRPO Efficiency
| Revenue/Employee | 308,866.667 |
| Income Per Employee | -71,500.00 |
| Receivables Turnover | 23.194 |
| Total Asset Turnover | 1.056 |
PRPO Liquidity
| Current Ratio | 0.808 |
| Quick Ratio | 0.638 |
| Cash Ratio | 0.325 |
PRPO Profitability
| Gross Margin | 32.625 |
| Operating Margin | -22.75 |
| Pretax Margin | -23.149 |
| Net Margin | -23.149 |
| Return on Assets | -24.447 |
| Return on Equity | -32.349 |
| Return on Total Capital | -32.142 |
| Return on Invested Capital | -30.992 |
PRPO Capital Structure
| Total Debt to Total Equity | 10.361 |
| Total Debt to Total Capital | 9.388 |
| Total Debt to Total Assets | 7.372 |
| Long-Term Debt to Equity | 5.217 |
| Long-Term Debt to Total Capital | 4.728 |